1. GPCR/G Protein
  2. GNRH Receptor
  3. Abarelix

Abarelix (Synonyms: R3827; PPI 149)

Cat. No.: HY-13534 Purity: 96.27%
Handling Instructions

Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

For research use only. We do not sell to patients.

Abarelix Chemical Structure

Abarelix Chemical Structure

CAS No. : 183552-38-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 467 In-stock
Estimated Time of Arrival: December 31
5 mg USD 180 In-stock
Estimated Time of Arrival: December 31
10 mg USD 300 In-stock
Estimated Time of Arrival: December 31
25 mg USD 660 In-stock
Estimated Time of Arrival: December 31
50 mg USD 1140 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Abarelix:

Top Publications Citing Use of Products

Publications Citing Use of MCE Abarelix

    Abarelix purchased from MCE. Usage Cited in: Am J Physiol Endocrinol Metab. 2020 May 12.

    EPHA7, ERα, and ERβ protein expression in the hypothalamus of abarelix-treated rats injected with EPHA7-Fc.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

    In Vitro

    Abarelix (30 and 300 µg/mL) causes significantly increased histamine release[1]. Abarelix is the first GnRH antagonist to be developed, and can produce rapid and sustained decreases in testosterone to castrate levels without the need for co-administration of an antiandrogen, and with a very low complication rate in the short term[2]. Abarelix demonstrates to promptly and substantially reduce follicle-stimulating hormone levels to lower than LHRH agonist. Abarelix does not cause a surge in serum testosterone that can precipitate a flare phenomenon or worsening of disease, particularly dangerous for patients with metastatic, symptomatic disease, and produces medical castration more quickly[3].

    Clinical Trial
    Molecular Weight

    1416.06

    Formula

    C₇₂H₉₅ClN₁₄O₁₄

    CAS No.

    183552-38-7

    Sequence

    Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-Ser-{NMeTyr}-{d-Asp}-Leu-Lys(ipr)-Pro-{d-Ala}-NH2

    Sequence Shortening

    Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-S-{NMyr}-{d-Asp}-L-K(ipr)-P-{d-Ala}-NH2

    SMILES

    C[[email protected]](C(N)=O)NC([[email protected]]1N(C([[email protected]](CCCCNC(C)C)NC([[email protected]](CC(C)C)NC([[email protected]@H](CC(N)=O)NC([[email protected]](CC2=CC=C(C=C2)O)N(C([[email protected]](CO)NC([[email protected]@H](CC3=CC=CN=C3)NC([[email protected]@H](CC4=CC=C(Cl)C=C4)NC([[email protected]@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CCC1)=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -80°C 2 years
      -20°C 1 year
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 14.2 mg/mL (10.03 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.7062 mL 3.5309 mL 7.0618 mL
    5 mM 0.1412 mL 0.7062 mL 1.4124 mL
    10 mM 0.0706 mL 0.3531 mL 0.7062 mL
    *Please refer to the solubility information to select the appropriate solvent.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    AbarelixR3827PPI 149R 3827R-3827PPI149PPI-149GNRH ReceptorGonadotropin releasing hormone receptorGNRHRInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product name:
    Abarelix
    Cat. No.:
    HY-13534
    Quantity:
    MCE Japan Authorized Agent: